Search
Policy on double awarding
We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.
Read moreHow to apply for TRTH
Download the letter of intent template. Fill in the template and get it duly signed. When you are ready, access the EHA Portal at http://eha. fluxx. io. and register yourself by clicking on the ‘Create an Account’ button.
Read morePolicy on double awarding
We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.
Read moreSelected EMA news
January 2025New medicines recommended for approval
Rytelo (imetelstat sodium) - orphan
Treatment of anemia (low levels of red blood cells)
Zefylti (filgrastim) – biosimilar
Treatment of neutropenia (low level of white blood cells) in patients having chemotherapy or a bone marrow transplant
New…
Sponsor Opportunities
The European Hematology Association (EHA) invites you to support the 7th European CAR T-cell Meeting.
Read moreAbstract & Clinical Case Submission and Travel Grant
Submit your abstract here
Abstract and clinical case procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time…
EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease
November 10-11, 2022 | Bordeaux, France
Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.
Press release: 18th Congress of the European Hematology Association in Stockholm, Sweden June 13-16-2013
The EHA-theme of the year, from June 2013 to June 2014, is dedicated to “Age and Aging in blood disorders”.
Read moreInvitation: “Can EU citizens afford their medicines? The economic crisis and access to medicines in Europe“
For more information, please find the full invitation here
Read moreReduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial
Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- »